|
Mutation Information
|
Mutation Site
|
K219R |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
bictegravir (BIC);emtricitabine (FTC);tenofovir (TDF);dolutegravir (DTG);abacavir (ABC);lamivudine (LAM) |
|
Country
|
Australia;Europe;Latin America;North America |
Literature Information
|
PubMed PMID
|
33880558
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2021 |
|
Journal
|
The Journal of antimicrobial chemotherapy |
|
Title
|
Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants. |
|
Author
|
Acosta RK,Chen GQ,Chang S,Martin R,Wang X,Huang H,Brainard D,Collins SE,Martin H,White KL |
|
Evidence
|
Primary NRTI resistance substitutions were observed in 2.7% (35/1274) of participants (Table 1); the most frequent were the TAMs M41L or K219E/N/Q/R in RT.
|
|
|
HIV Mutation Detail Information